{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T14:55:33Z","timestamp":1786460133098,"version":"build-2736575974"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100018693","name":"HORIZON EUROPE Framework Programme","doi-asserted-by":"publisher","award":["899871"],"award-info":[{"award-number":["899871"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s10557-025-07825-8","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T02:51:23Z","timestamp":1770864683000},"page":"1485-1502","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Potentially Clinically Significant Drug-Drug Interactions in Older Adults with Atrial Fibrillation and Multimorbidity: Prevalence, Correlates, and Association with Adverse Clinical Outcomes in a Swedish National Register-Based Study"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6708-7372","authenticated-orcid":false,"given":"Cheima","family":"Amrouch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide Liborio","family":"Vetrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"De Bacquer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Ferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ine","family":"Simal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Damiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaia","family":"Calder\u00f3n-Larra\u00f1aga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid D. H.","family":"Brys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"De Spiegeleer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren P.","family":"Johnsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas W.","family":"Wastesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Johnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"De Smedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Petrovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"7825_CR1","doi-asserted-by":"publisher","unstructured":"Hines LE, Murphy JE. Potentially harmful drug-drug interactions in the elderly: a review. Am J Geriatr Pharmacother. 2011;9(6):364\u2009\u2013\u200977. https:\/\/doi.org\/10.1016\/j.amjopharm.2011.10.004.\u00a0","DOI":"10.1016\/j.amjopharm.2011.10.004"},{"issue":"10","key":"7825_CR2","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1111\/jgs.19035","volume":"72","author":"M Carollo","year":"2024","unstructured":"Carollo M, Crisafulli S, Vitturi G, et al. Clinical impact of medication review and deprescribing in older inpatients: A systematic review and meta-analysis. J Am Geriatr Soc. 2024;72(10):3219\u201338. https:\/\/doi.org\/10.1111\/jgs.19035.","journal-title":"J Am Geriatr Soc"},{"key":"7825_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s41999-024-01025-7","author":"I Simal","year":"2024","unstructured":"Simal I, Somers A, Amrouch C, et al. A descriptive analysis of drug-drug interactions and corresponding adverse drug reactions in multimorbid older inpatients: findings from the SENATOR trial. Eur Geriatr Med. 2024. https:\/\/doi.org\/10.1007\/s41999-024-01025-7.","journal-title":"Eur Geriatr Med"},{"issue":"6","key":"7825_CR4","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40261-024-01369-9","volume":"44","author":"JE Hughes","year":"2024","unstructured":"Hughes JE, Bennett KE, Cahir C. Drug-drug interactions and their association with adverse health outcomes in the older community-dwelling population: a prospective cohort study. Clin Drug Investig. 2024;44(6):439\u201353. https:\/\/doi.org\/10.1007\/s40261-024-01369-9.","journal-title":"Clin Drug Investig"},{"issue":"9","key":"7825_CR5","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.ejim.2014.10.001","volume":"25","author":"A Marengoni","year":"2014","unstructured":"Marengoni A, Pasina L, Concoreggi C, et al. Understanding adverse drug reactions in older adults through drug-drug interactions. Eur J Intern Med. 2014;25(9):843\u20136. https:\/\/doi.org\/10.1016\/j.ejim.2014.10.001.","journal-title":"Eur J Intern Med"},{"issue":"6","key":"7825_CR6","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/pds.5415","volume":"31","author":"C Leal Rodriguez","year":"2022","unstructured":"Leal Rodriguez C, Kaas-Hansen BS, Eriksson R, et al. Drug interactions in hospital prescriptions in denmark: prevalence and associations with adverse outcomes. Pharmacoepidemiol Drug Saf. 2022;31(6):632\u201342. https:\/\/doi.org\/10.1002\/pds.5415.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"7825_CR7","doi-asserted-by":"publisher","first-page":"911","DOI":"10.2165\/00002018-200730100-00009","volume":"30","author":"K Johnell","year":"2007","unstructured":"Johnell K, Klarin I. The relationship between number of drugs and potential drug-drug interactions in the elderly - a study of over 600 000 elderly patients from the Swedish prescribed drug register. Drug Saf. 2007;30(10):911\u20138. https:\/\/doi.org\/10.2165\/00002018-200730100-00009.","journal-title":"Drug Saf"},{"issue":"2","key":"7825_CR8","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00228-007-0422-1","volume":"64","author":"S Shi","year":"2008","unstructured":"Shi S, M\u00f6rike K, Klotz U. The clinical implications of ageing for rational drug therapy. Eur J Clin Pharmacol. 2008;64(2):183\u201399. https:\/\/doi.org\/10.1007\/s00228-007-0422-1.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"7825_CR9","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.cger.2012.01.007","volume":"28","author":"LC Sera","year":"2012","unstructured":"Sera LC, McPherson ML. Pharmacokinetics and pharmacodynamic changes associated with aging and implications for drug therapy. Clin Geriatr Med. 2012;28(2):273. https:\/\/doi.org\/10.1016\/j.cger.2012.01.007.","journal-title":"Clin Geriatr Med"},{"issue":"9582","key":"7825_CR10","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0140-6736(07)61092-7","volume":"370","author":"L Mallet","year":"2007","unstructured":"Mallet L, Spinewine A, Huang A. The challenge of managing drug interactions in elderly people. Lancet. 2007;370(9582):185\u201391. https:\/\/doi.org\/10.1016\/S0140-6736(07)61092-7.","journal-title":"Lancet"},{"key":"7825_CR11","doi-asserted-by":"publisher","unstructured":"Zerah L, Henrard S, Wilting I, et al. Prevalence of drug-drug interactions in older people before and after hospital admission: analysis from the OPERAM trial. BMC Geriatr. 2021;21(1). https:\/\/doi.org\/10.1186\/s12877-021-02532-z.","DOI":"10.1186\/s12877-021-02532-z"},{"key":"7825_CR12","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.thromres.2024.05.006","volume":"238","author":"A Capiau","year":"2024","unstructured":"Capiau A, Mehuys E, Grymonprez M, et al. Detection and management of clinically relevant drug-drug interactions with direct oral anticoagulants: an intervention study in community pharmacies. Thromb Res. 2024;238:223\u201331. https:\/\/doi.org\/10.1016\/j.thromres.2024.05.006.","journal-title":"Thromb Res"},{"issue":"6","key":"7825_CR13","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s10557-018-6825-7","volume":"32","author":"X Feng","year":"2018","unstructured":"Feng X, Sambamoorthi U, Innes K, et al. Predictors of major bleeding among Working-Age adults with atrial fibrillation: evaluating the effects of potential Drug-drug interactions and switching from warfarin to Non-vitamin K oral anticoagulants. Cardiovasc Drugs Ther. 2018;32(6):591\u2013600. https:\/\/doi.org\/10.1007\/s10557-018-6825-7.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7825_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-023-07521-5","author":"M Grymonprez","year":"2023","unstructured":"Grymonprez M, Capiau A, Steurbaut S, et al. Pharmacodynamic Drug-Drug interactions and bleeding outcomes in patients with atrial fibrillation using Non-Vitamin K antagonist oral anticoagulants: a nationwide cohort study. Cardiovasc Drugs Ther. 2023. https:\/\/doi.org\/10.1007\/s10557-023-07521-5.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"3","key":"7825_CR15","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s10557-023-07499-0","volume":"38","author":"M Ioannou","year":"2024","unstructured":"Ioannou M, Leonidou E, Chaziri I, Mouzarou A. Direct oral anticoagulants: navigating through clinical challenges. Cardiovasc Drugs Ther. 2024;38(3):637\u201350. https:\/\/doi.org\/10.1007\/s10557-023-07499-0.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"36","key":"7825_CR16","doi-asserted-by":"publisher","first-page":"p3314","DOI":"10.1093\/eurheartj\/ehae176","volume":"45","author":"IC Van Gelder","year":"2024","unstructured":"Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European association for Cardio-Thoracic surgery (EACTS). Eur Heart J. 2024;45(36):p3314\u20133414. https:\/\/doi.org\/10.1093\/eurheartj\/ehae176.","journal-title":"Eur Heart J"},{"key":"7825_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-025-07691-4","author":"SCM Wuyts","year":"2025","unstructured":"Wuyts SCM, Bonte S, Thielemans N, et al. Interactions between direct oral anticoagulants and drugs involving CYP-Enzymes and P-gp transporters detected by a clinical decision support system: A retrospective cohort study. Cardiovasc Drugs Ther. 2025. https:\/\/doi.org\/10.1007\/s10557-025-07691-4.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7825_CR18","doi-asserted-by":"publisher","unstructured":"Chao TF, Joung B, Takahashi Y et al. 2021 Focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation. J Arrhythm, 2021. 37(6): pp. 1389\u20131426; https:\/\/doi.org\/10.1002\/joa3.12652","DOI":"10.1002\/joa3.12652"},{"key":"7825_CR19","doi-asserted-by":"publisher","unstructured":"Wang Y, Guo Y, Qin M et al. 2024 Chinese Expert Consensus Guidelines on the Diagnosis and Treatment of Atrial Fibrillation in the Elderly, Endorsed by Geriatric Society of Chinese Medical Association (Cardiovascular Group) and Chinese Society of Geriatric Health Medicine (Cardiovascular Branch): Executive Summary. Thromb Haemost, 2024. 124(10): pp. 897\u2013911; https:\/\/doi.org\/10.1055\/a-2325-5923","DOI":"10.1055\/a-2325-5923"},{"key":"7825_CR20","unstructured":"Socialstyrelsen. Registers. Accessed 2022; Available from: https:\/\/www.socialstyrelsen.se\/en\/statistics-and-data\/registers\/"},{"issue":"2","key":"7825_CR21","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10654-016-0117-y","volume":"31","author":"JF Ludvigsson","year":"2016","unstructured":"Ludvigsson JF, Almqvist C, Bonamy AKE, et al. Registers of the Swedish total population and their use in medical research. Eur J Epidemiol. 2016;31(2):125\u201336. https:\/\/doi.org\/10.1007\/s10654-016-0117-y.","journal-title":"Eur J Epidemiol"},{"key":"7825_CR22","unstructured":"Socialstyrelsen. The Education Register. Accessed 2023; Available from: https:\/\/rut.registerforskning.se\/metadatakatalog\/register\/44bd4733-6db9-44bf-92c6-0b608450cd7b\/."},{"key":"7825_CR23","unstructured":"Socialstyrelsen. National Patient Register. Accessed 2022; Available from: https:\/\/www.socialstyrelsen.se\/en\/statistics-and-data\/registers\/national-patient-register\/"},{"issue":"10","key":"7825_CR24","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1093\/gerona\/glw233","volume":"72","author":"A Calderon-Larranaga","year":"2017","unstructured":"Calderon-Larranaga A, Vetrano DL, Onder G, et al. Assessing and measuring chronic Multimorbidity in the older population: A proposal for its operationalization. J Gerontol Biol Sci Med Sci. 2017;72(10):1417\u201323. https:\/\/doi.org\/10.1093\/gerona\/glw233.","journal-title":"J Gerontol Biol Sci Med Sci"},{"key":"7825_CR25","unstructured":"Socialstyrelsen. National Prescribed Drug Register. Accessed 2022; Available from: https:\/\/www.socialstyrelsen.se\/en\/statistics-and-data\/registers\/national-prescribed-drug-register\/"},{"key":"7825_CR26","unstructured":"Socialstyrelsen. National Cause of Death Register. Accessed 2024; Available from: https:\/\/www.socialstyrelsen.se\/en\/statistics-and-data\/registers\/national-cause-of-death--register\/"},{"key":"7825_CR27","doi-asserted-by":"publisher","first-page":"1476464","DOI":"10.3389\/fphar.2024.1476464","volume":"15","author":"C Amrouch","year":"2024","unstructured":"Amrouch C, Vetrano DL, Damiano C, et al. Potentially inappropriate prescribing in polymedicated older adults with atrial fibrillation and multimorbidity: a Swedish National register-based cohort study. Front Pharmacol. 2024;15:1476464. https:\/\/doi.org\/10.3389\/fphar.2024.1476464.","journal-title":"Front Pharmacol"},{"issue":"10","key":"7825_CR28","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1016\/j.jamda.2021.03.019","volume":"22","author":"P Anrys","year":"2021","unstructured":"Anrys P, Petit AE, Thevelin S, et al. An international consensus list of potentially clinically significant Drug-Drug interactions in older people. J Am Med Dir Assoc. 2021;22(10):2121\u2013e213324. https:\/\/doi.org\/10.1016\/j.jamda.2021.03.019.","journal-title":"J Am Med Dir Assoc"},{"key":"7825_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14061120","author":"N Ferri","year":"2022","unstructured":"Ferri N, Colombo E, Tenconi M, Baldessin L, Corsini A. Drug-Drug interactions of direct oral anticoagulants (DOACs): from pharmacological to clinical practice. Pharmaceutics. 2022. https:\/\/doi.org\/10.3390\/pharmaceutics14061120.","journal-title":"Pharmaceutics"},{"key":"7825_CR30","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. The Anatomical Therapeutic Chemical Classification System with Defined Daily Doses (ATC\/DDD). Accessed 2021; Available from: https:\/\/www.whocc.no\/atc_ddd_index\/"},{"issue":"1","key":"7825_CR31","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1517\/14740338.2012.631910","volume":"11","author":"L Magro","year":"2012","unstructured":"Magro L, Moretti U, Leone R. Epidemiology and characteristics of adverse drug reactions caused by drug-drug interactions. Expert Opin Drug Saf. 2012;11(1):83\u201394. https:\/\/doi.org\/10.1517\/14740338.2012.631910.","journal-title":"Expert Opin Drug Saf"},{"key":"7825_CR32","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12916-015-0322-7","volume":"13","author":"B Guthrie","year":"2015","unstructured":"Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995\u20132010. BMC Med. 2015;13:74. https:\/\/doi.org\/10.1186\/s12916-015-0322-7.","journal-title":"BMC Med"},{"issue":"12","key":"7825_CR33","doi-asserted-by":"publisher","first-page":"e0225297","DOI":"10.1371\/journal.pone.0225297","volume":"14","author":"K Momo","year":"2019","unstructured":"Momo K, Kobayashi H, Sugiura Y, et al. Prevalence of drug-drug interaction in atrial fibrillation patients based on a large claims data. PLoS ONE. 2019;14(12):e0225297. https:\/\/doi.org\/10.1371\/journal.pone.0225297.","journal-title":"PLoS ONE"},{"issue":"3","key":"7825_CR34","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s40266-015-0242-4","volume":"32","author":"J Fastbom","year":"2015","unstructured":"Fastbom J, Johnell K. National indicators for quality of drug therapy in older persons: the Swedish experience from the first 10 years. Drugs Aging. 2015;32(3):189\u201399. https:\/\/doi.org\/10.1007\/s40266-015-0242-4.","journal-title":"Drugs Aging"},{"key":"7825_CR35","doi-asserted-by":"publisher","first-page":"1432713","DOI":"10.3389\/fphar.2024.1432713","volume":"15","author":"T Bischof","year":"2024","unstructured":"Bischof T, Nagele F, Kalkofen MM, et al. Drug-drug-interactions in patients with atrial fibrillation admitted to the emergency department. Front Pharmacol. 2024;15:1432713. https:\/\/doi.org\/10.3389\/fphar.2024.1432713.","journal-title":"Front Pharmacol"},{"issue":"2","key":"7825_CR36","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s40266-022-01001-5","volume":"40","author":"JE Hughes","year":"2023","unstructured":"Hughes JE, Waldron C, Bennett KE, Cahir C. Prevalence of drug-drug interactions in older community-dwelling individuals: a systematic review and meta-analysis. Drugs Aging. 2023;40(2):117\u201334. https:\/\/doi.org\/10.1007\/s40266-022-01001-5.","journal-title":"Drugs Aging"},{"issue":"12","key":"7825_CR37","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1111\/ggi.13070","volume":"17","author":"TRA Santos","year":"2017","unstructured":"Santos TRA, Silveira EA, Pereira LV, et al. Potential drug-drug interactions in older adults: A population-based study. Geriatr Gerontol Int. 2017;17(12):2336\u201346. https:\/\/doi.org\/10.1111\/ggi.13070.","journal-title":"Geriatr Gerontol Int"},{"key":"7825_CR38","doi-asserted-by":"publisher","first-page":"589","DOI":"10.2147\/JMDH.S297423","volume":"14","author":"M Hermann","year":"2021","unstructured":"Hermann M, Carstens N, Kvinge L, et al. Polypharmacy and potential Drug-Drug interactions in Home-Dwelling older People - A Cross-Sectional study. J Multidiscip Healthc. 2021;14:589\u201397. https:\/\/doi.org\/10.2147\/JMDH.S297423.","journal-title":"J Multidiscip Healthc"},{"issue":"2","key":"7825_CR39","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00228-014-1786-7","volume":"71","author":"T Roblek","year":"2015","unstructured":"Roblek T, Vaupotic T, Mrhar A, Lainscak M. Drug-drug interaction software in clinical practice: a systematic review. Eur J Clin Pharmacol. 2015;71(2):131\u201342. https:\/\/doi.org\/10.1007\/s00228-014-1786-7.","journal-title":"Eur J Clin Pharmacol"},{"key":"7825_CR40","doi-asserted-by":"publisher","first-page":"1088900","DOI":"10.3389\/fphar.2023.1088900","volume":"14","author":"Z Ocovska","year":"2023","unstructured":"Ocovska Z, Marikova M, Vlcek J. Potentially clinically significant drug-drug interactions in older patients admitted to the hospital: A cross-sectional study. Front Pharmacol. 2023;14:1088900. https:\/\/doi.org\/10.3389\/fphar.2023.1088900.","journal-title":"Front Pharmacol"},{"issue":"6","key":"7825_CR41","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.sapharm.2017.07.004","volume":"14","author":"J Jazbar","year":"2018","unstructured":"Jazbar J, Locatelli I, Horvat N, Kos M. Clinically relevant potential druge-drug interactions among outpatients: a nationwide database study. Res Social Adm Pharm. 2018;14(6):572\u201380. https:\/\/doi.org\/10.1016\/j.sapharm.2017.07.004.","journal-title":"Res Social Adm Pharm"},{"issue":"4","key":"7825_CR42","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1111\/bcp.15970","volume":"90","author":"JE Hughes","year":"2024","unstructured":"Hughes JE, Moriarty F, Bennett KE, Cahir C. Drug-drug interactions and the risk of adverse drug reaction-related hospital admissions in the older population. Br J Clin Pharmacol. 2024;90(4):959\u201375. https:\/\/doi.org\/10.1111\/bcp.15970.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"7825_CR43","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/pds.1351","volume":"16","author":"ML Becker","year":"2007","unstructured":"Becker ML, Kallewaard M, Caspers PWJ, et al. Hospitalisations and emergency department visits due to drug-drug interactions: a literature review. Pharmacoepidemiol Drug Saf. 2007;16(6):641\u201351. https:\/\/doi.org\/10.1002\/pds.1351.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"7825_CR44","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ejim.2012.09.011","volume":"24","author":"C Bucsa","year":"2013","unstructured":"Bucsa C, Farcas A, Cazacu I, et al. How many potential drug-drug interactions cause adverse drug reactions in hospitalized patients? Eur J Intern Med. 2013;24(1):27\u201333. https:\/\/doi.org\/10.1016\/j.ejim.2012.09.011.","journal-title":"Eur J Intern Med"},{"issue":"2","key":"7825_CR45","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1365-2125.2009.03443.x","volume":"68","author":"JE Zwart-van Rijkom","year":"2009","unstructured":"Zwart-van Rijkom JE, Uijtendaal EV, ten Berg MJ, van Solinge WW, Egberts AC. Frequency and nature of drug-drug interactions in a Dutch university hospital. Br J Clin Pharmacol. 2009;68(2):187\u201393. https:\/\/doi.org\/10.1111\/j.1365-2125.2009.03443.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"7825_CR46","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/j.1532-5415.1996.tb01865.x","volume":"44","author":"J Doucet","year":"1996","unstructured":"Doucet J, Chassagne P, Trivalle C, et al. Drug-drug interactions related to hospital admissions in older adults: a prospective study of 1000 patients. J Am Geriatr Soc. 1996;44(8):944\u20138. https:\/\/doi.org\/10.1111\/j.1532-5415.1996.tb01865.x.","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"7825_CR47","doi-asserted-by":"publisher","first-page":"22403","DOI":"10.1038\/s41598-021-01786-2","volume":"11","author":"JY Lee","year":"2021","unstructured":"Lee JY, Oh IY, Lee JH, et al. Drug-drug interactions in atrial fibrillation patients receiving direct oral anticoagulants. Sci Rep. 2021;11(1):22403. https:\/\/doi.org\/10.1038\/s41598-021-01786-2.","journal-title":"Sci Rep"},{"issue":"6","key":"7825_CR48","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1111\/bcp.14227","volume":"86","author":"YM Zhang","year":"2020","unstructured":"Zhang YM, Souverein PC, Gardarsdottir H, et al. Risk of major bleeding among users of direct oral anticoagulants combined with interacting drugs: A population-based nested case-control study. Br J Clin Pharmacol. 2020;86(6):1150\u201364. https:\/\/doi.org\/10.1111\/bcp.14227.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"7825_CR49","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00228-020-03015-7","volume":"77","author":"J Holm","year":"2021","unstructured":"Holm J, Mannheimer B, Malmstr\u00f6m RE, Eliasson E, Lindh JD. Bleeding and thromboembolism due to drug-drug interactions with non-vitamin K antagonist oral anticoagulants-a Swedish, register-based cohort study in atrial fibrillation outpatients. Eur J Clin Pharmacol. 2021;77(3):409\u201319. https:\/\/doi.org\/10.1007\/s00228-020-03015-7.","journal-title":"Eur J Clin Pharmacol"},{"key":"7825_CR50","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.thromres.2023.03.007","volume":"231","author":"SFB van der Horst","year":"2023","unstructured":"van der Horst SFB, van Rein N, van Mens TE, Huisman MV, Klok FA. Inappropriate prescriptions of direct oral anticoagulants (DOACs) in hospitalized patients: A narrative review. Thromb Res. 2023;231:135\u201340. https:\/\/doi.org\/10.1016\/j.thromres.2023.03.007.","journal-title":"Thromb Res"},{"key":"7825_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13072009","author":"D Poli","year":"2024","unstructured":"Poli D, Antonucci E, Ageno W, et al. Inappropriate underdosing of direct oral anticoagulants in atrial fibrillation patients: results from the START2-AF registry. J Clin Med. 2024. https:\/\/doi.org\/10.3390\/jcm13072009.","journal-title":"J Clin Med"},{"key":"7825_CR52","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.amjcard.2020.12.062","volume":"144","author":"A Sugrue","year":"2021","unstructured":"Sugrue A, Sanborn D, Amin M, et al. Inappropriate dosing of direct oral anticoagulants in patients with atrial fibrillation. Am J Cardiol. 2021;144:52\u20139. https:\/\/doi.org\/10.1016\/j.amjcard.2020.12.062.","journal-title":"Am J Cardiol"},{"key":"7825_CR53","doi-asserted-by":"publisher","first-page":"101598","DOI":"10.1016\/j.ijcha.2025.101598","volume":"56","author":"M Yildirim","year":"2025","unstructured":"Yildirim M, Hund H, Mueller-Hennessen M, et al. Clinical impact of inappropriate DOAC dosing in atrial fibrillation: insights from a real-world registry. IJC Heart Vasculature. 2025;56:101598. https:\/\/doi.org\/10.1016\/j.ijcha.2025.101598.","journal-title":"IJC Heart Vasculature"},{"issue":"7","key":"7825_CR54","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1111\/jgs.18894","volume":"72","author":"MJ de Jong","year":"2024","unstructured":"de Jong MJ, Saadan H, Hellenbrand DLS, et al. The DOAC-FRAIL study, evaluation of direct oral anticoagulant-levels in acutely admitted frail older patients: an exploratory study. J Am Geriatr Soc. 2024;72(7):2249\u201353. https:\/\/doi.org\/10.1111\/jgs.18894.","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"7825_CR55","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s10557-021-07232-9","volume":"37","author":"W Xu","year":"2023","unstructured":"Xu W, Lv M, Wu S, et al. Severe bleeding risk of direct oral anticoagulants versus vitamin K antagonists for stroke prevention and treatment in patients with atrial fibrillation: A systematic review and network Meta-Analysis. Cardiovasc Drugs Ther. 2023;37(2):363\u201377. https:\/\/doi.org\/10.1007\/s10557-021-07232-9.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"5","key":"7825_CR56","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1007\/s10557-021-07211-0","volume":"36","author":"R Benamouzig","year":"2022","unstructured":"Benamouzig R, Guenoun M, Deutsch D, Fauchier L. Review article: Gastrointestinal bleeding risk with direct oral anticoagulants. Cardiovasc Drugs Ther. 2022;36(5):973\u201389. https:\/\/doi.org\/10.1007\/s10557-021-07211-0.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"3\u20134","key":"7825_CR57","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1159\/000449376","volume":"76","author":"S Caratozzolo","year":"2016","unstructured":"Caratozzolo S, Gipponi S, Marengoni A, et al. Potentially serious Drug-Drug interactions in older patients hospitalized for acute ischemic and hemorrhagic stroke. Eur Neurol. 2016;76(3\u20134):161\u20136. https:\/\/doi.org\/10.1159\/000449376.","journal-title":"Eur Neurol"},{"issue":"4","key":"7825_CR58","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s10557-021-07279-8","volume":"37","author":"M Grymonprez","year":"2023","unstructured":"Grymonprez M, Vanspranghe K, Steurbaut S, De Backer TL, Lahousse L. Non-vitamin K antagonist oral anticoagulants (NOACs) versus warfarin in patients with atrial fibrillation using P-gp and\/or CYP450-Interacting drugs: a systematic review and Meta-analysis. Cardiovasc Drugs Ther. 2023;37(4):781\u201391. https:\/\/doi.org\/10.1007\/s10557-021-07279-8.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"3","key":"7825_CR59","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s10557-014-6524-y","volume":"28","author":"A Jalota","year":"2014","unstructured":"Jalota A, Scarabelli TM, Saravolatz L, et al. Novel anticoagulants for stroke prevention in patients with atrial fibrillation. Cardiovasc Drugs Ther. 2014;28(3):247\u201362. https:\/\/doi.org\/10.1007\/s10557-014-6524-y.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"4","key":"7825_CR60","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1093\/ageing\/afaa249","volume":"50","author":"LJ Seppala","year":"2021","unstructured":"Seppala LJ, Petrovic M, Ryg J, et al. STOPPFall (Screening tool of older persons prescriptions in older adults with high fall risk): a Delphi study by the EuGMS task and finish group on Fall-Risk-Increasing drugs. Age Ageing. 2021;50(4):1189\u201399. https:\/\/doi.org\/10.1093\/ageing\/afaa249.","journal-title":"Age Ageing"},{"issue":"3","key":"7825_CR61","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s10557-020-06979-x","volume":"35","author":"JM Castaldelli-Maia","year":"2021","unstructured":"Castaldelli-Maia JM, Hofmann C, Chagas ACP, et al. Major Cardiac-Psychiatric drug-Drug interactions: a systematic review of the consistency of drug databases. Cardiovasc Drugs Ther. 2021;35(3):441\u201354. https:\/\/doi.org\/10.1007\/s10557-020-06979-x.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"11","key":"7825_CR62","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nrcardio.2017.153","volume":"14","author":"GYH Lip","year":"2017","unstructured":"Lip GYH. The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol. 2017;14(11):627\u20138. https:\/\/doi.org\/10.1038\/nrcardio.2017.153.","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"7825_CR63","doi-asserted-by":"publisher","first-page":"3","DOI":"10.5935\/abc.20150049","volume":"105","author":"ED Almeida","year":"2015","unstructured":"Almeida ED, Guimaraes RB, Stephan LS, et al. Clinical differences between subtypes of atrial fibrillation and flutter: Cross-Sectional registry of 407 patients. Arquivos Brasileiros De Cardiologia. 2015;105(1):3\u201310. https:\/\/doi.org\/10.5935\/abc.20150049.","journal-title":"Arquivos Brasileiros De Cardiologia"},{"issue":"9","key":"7825_CR64","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1007\/s40520-022-02140-w","volume":"34","author":"A Di Carlo","year":"2022","unstructured":"Di Carlo A, Mori F, Consoli D, et al. Influence of atrial fibrillation subtypes on anticoagulant therapy in a high-risk older population: the FAI project. Aging Clin Exp Res. 2022;34(9):2185\u201394. https:\/\/doi.org\/10.1007\/s40520-022-02140-w.","journal-title":"Aging Clin Exp Res"},{"issue":"2","key":"7825_CR65","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jacep.2017.09.002","volume":"4","author":"M Leung","year":"2018","unstructured":"Leung M, van Rosendael PJ, Abou R, et al. The impact of atrial fibrillation clinical subtype on mortality. JACC Clin Electrophysiol. 2018;4(2):221\u20137. https:\/\/doi.org\/10.1016\/j.jacep.2017.09.002.","journal-title":"JACC Clin Electrophysiol"},{"issue":"5","key":"7825_CR66","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1093\/eurheartj\/ehu307","volume":"36","author":"T Vanassche","year":"2015","unstructured":"Vanassche T, Lauw MN, Eikelboom JW, et al. Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. Eur Heart J. 2015;36(5):281\u2013a7. https:\/\/doi.org\/10.1093\/eurheartj\/ehu307.","journal-title":"Eur Heart J"},{"issue":"7","key":"7825_CR67","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1093\/eurheartj\/ehn101","volume":"29","author":"R Nieuwlaat","year":"2008","unstructured":"Nieuwlaat R, Dinh T, Olsson SB, et al. Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation? Eur Heart J. 2008;29(7):915\u201322. https:\/\/doi.org\/10.1093\/eurheartj\/ehn101.","journal-title":"Eur Heart J"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07825-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-025-07825-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07825-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T09:07:34Z","timestamp":1784624854000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-025-07825-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":67,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["7825"],"URL":"https:\/\/doi.org\/10.1007\/s10557-025-07825-8","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"assertion":[{"value":"27 November 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The studies involving humans were approved by Ethical approval was granted by the Regional Ethical Review Board of Stockholm (dnr: 2016\/1001\u201331\/4, 356 2020\u201303525; 2021\u201302004). The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required from the participants or the participants\u2019 legal guardians\/next of kin because the data sources are national health registers.","order":1,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent for publication was not required from the participants or the participants\u2019 legal guardians\/next of kin because the data sources are national health registers.","order":2,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent for participation was not required from the participants or the participants\u2019 legal guardians\/next of kin because the data sources are national health registers.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LD is employed by Vantive. GL declares consultancy and speaker fees from BMS\/Pfizer, Boehringer Ingelheim and\u00a0Daiichi-Sankyo. The remaining authors declare that the research was conducted in the absence of any commercial\u00a0or financial relationships that could be construed as a potential conflict of interest.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}